Literature DB >> 17071165

Coccidioidomycosis in patients with diabetes mellitus.

Ana C Santelli1, Janis E Blair, Lori R Roust.   

Abstract

PURPOSE: The study reviewed the interrelationships of diabetes mellitus and coccidioidomycosis. SUBJECTS AND METHODS: We conducted a retrospective review of the medical records of immunocompetent patients with coccidioidomycosis who were treated at our academic medical institution between January 1, 1999, and October 31, 2003, to compare those with and without diabetes mellitus and to determine whether glycemia correlates with the course of illness.
RESULTS: Of 329 immunocompetent patients with coccidioidomycosis, 44 had diabetes (4 type 1 and 40 type 2) and were divided into 2 groups: those with serum glucose concentrations of less than 12.2 mmol/L (220 mg/dL) and those with glucose concentrations of greater than or equal to 12.2 mmol/L (220 mg/dL). Persons with diabetes in either glucose group were more likely than those without diabetes to have cavitary lung disease (relative risk, 2.94; P<.001) and relapsed infection. However, only the diabetes group with serum glucose concentrations greater than or equal to 12.2 mmol/L (220 mg/dL) were more likely to have disseminated infection (relative risk, 2.8; P=.05) and to require treatment (relative risk, 9.85; P=.005), but their infection was less likely to resolve (relative risk, 0.24; P=.002).
CONCLUSION: Because glycemia strongly correlated with clinical characteristics of coccidioidomycosis in this cohort, we recommend routine measurement of serum glucose in persons with coccidioidomycosis to identify patients with an increased risk of complicated infection. Future studies should evaluate the efficacy of tight glycemic control on the outcome of coccidioidal infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17071165     DOI: 10.1016/j.amjmed.2006.03.033

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  23 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

2.  The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis.

Authors:  Nathan P Wiederhold; Lisa F Shubitz; Laura K Najvar; Rosie Jaramillo; Marcos Olivo; Gabriel Catano; Hien T Trinh; Christopher M Yates; Robert J Schotzinger; Edward P Garvey; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 3.  How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts.

Authors:  Steven T Denham; Morgan A Wambaugh; Jessica C S Brown
Journal:  J Mol Biol       Date:  2019-05-09       Impact factor: 5.469

Review 4.  Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Authors:  Chinh Nguyen; Bridget Marie Barker; Susan Hoover; David E Nix; Neil M Ampel; Jeffrey A Frelinger; Marc J Orbach; John N Galgiani
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 5.  Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.

Authors:  Elizabeth J Polvi; Xinliu Li; Teresa R O'Meara; Michelle D Leach; Leah E Cowen
Journal:  Cell Mol Life Sci       Date:  2015-02-21       Impact factor: 9.261

6.  A 37-Year-Old Man With Pleuritic Chest Pain.

Authors:  Jessica Galant-Swafford; Matthew Light; Mark W Onaitis; Stephen A Rawlings; Joshua Fierer; Judd W Landsberg
Journal:  Chest       Date:  2019-07       Impact factor: 9.410

7.  Disseminated Coccidioidomycosis with Clinically Evident Splenomegaly in an Immunocompetent Host, First Case Reported in the literature.

Authors:  Garrett R Bird; Robert D Libke; John F Billelo; Nancy A Parks; John S Pollard
Journal:  Mcgill J Med       Date:  2009-11-16

8.  Mycelial forms of Coccidioides spp. in the parasitic phase associated to pulmonary coccidioidomycosis with type 2 diabetes mellitus.

Authors:  B Muñoz-Hernández; M A Martínez-Rivera; G Palma Cortés; A Tapia-Díaz; M E Manjarrez Zavala
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-30       Impact factor: 3.267

9.  Coccidioidal meningitis: update on epidemiology, clinical features, diagnosis, and management.

Authors:  Janis E Blair
Journal:  Curr Infect Dis Rep       Date:  2009-07       Impact factor: 3.725

10.  A Case of Refractory Pulmonary Coccidioidomycosis Successfully Treated with Posaconazole Therapy.

Authors:  R H Patel; S Pandya; S Nanjappa; J N Greene
Journal:  J Fam Med       Date:  2017-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.